-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
On December 17, Suoyuan Biotech announced that the company used its unique biomarker discovery platform to successfully discover a new biomarker of DB107, a gene therapy for recurrent high-grade glioma (HGG)-DGM7 (Denovo Genomic Marker 7)
DB107 is a new type of combination therapy obtained by Suoyuan Biotech from Tocagen.
According to the press release, in the international phase 3 clinical trial of Tocagen using DB107 for recurrent high-grade glioma, DB107 showed good safety and tolerability, but DB107 did not show better than the standard in the overall population The efficacy of the therapy
The study found that in the DB107 test group, the overall survival rate of DGM7-positive patients was significantly better than that of DGM7-negative patients, and it was also significantly better than patients using standard treatment
Prior to this, Suoyuan Biotechnology has successfully discovered 2 biomarkers for tumor treatment drugs and 1 biomarker for central nervous system disease drugs
In addition to DB107 for recurrent GBM, Suoyuan Biosciences is also conducting an international multi-center phase 3 clinical trial of DB102 for newly treated GBM patients.
